Therapeutic impact of ET-743 (Yondelis; trabectidin), a new marine-derived compound, in sarcoma

José Jimeno, Robert G. Maki, Paolo G. Casali, Glynn Faircloth, Nerea Martı́nez, Antonio Nieto, Salvador Cañigueral, Kenneth Rinehart

Current Opinion in Orthopedics · 2003 · 11 citations · 33 references

Concepts

Abstract

“Nature distributed medicine everywhere.” - Pliny the Elder, circa AD 77 Purpose of review: The therapeutic pharmacologic armamentarium in sarcoma is limited, and patients with advanced disease have a dismal prognosis. The onset of metastatic disease yields to median survival of 1 year. The identification of new active agents against sarcoma is one of the most important challenges in cancer research. Recent findings: ET-743 (Yondelis; trabectidin) is a marine-derived cytotoxic bearing an innovative mode of action. An extensive phase II program has confirmed activity and a therapeutic impact in the natural history of patients with advanced pretreated soft tissue sarcoma. Summary: The results generated in heavily pretreated bone sarcoma warrant further studies in less pretreated cases, and the early data released in Ewing sarcoma warrant further developmental efforts. The ongoing phase I program in combination therapy is expected to bring new paradigmatic models to allow further investigations in sarcoma. The specific correlation between the DNA repair capability and the sensitivity and resistance to ET-743 in experimental models provide a solid foundation to investigate whether such correlates are confirmed at the clinical level to establish further customized therapies to improve the outcome of patients with sarcoma.

References

33